ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™. “We are excited to expand our offering in nerve protection with the introduction of this resorbable barrier to support the critical phases of healing for nerve injuries,” said Karen Zaderej, chairman, CEO, and president.

佛罗里达州阿拉丘亚市和佛罗里达州坦帕市，2024年4月29日（环球通讯社）--Axogen，Inc.（纳斯达克：AXGN），一家开发和营销周围神经损伤创新手术解决方案的全球领导者，宣布其最新产品Avive+Soft Tissue Matrix™的首次手术植入。董事长、首席执行官兼总裁卡伦·扎德里吉（KarenZaderej）表示：“我们很高兴能够通过引入这种可再吸收的屏障来扩展我们在神经保护方面的产品，以支持神经损伤愈合的关键阶段。”。

“We are pleased with initial surgeon feedback and look forward to making Avive+ Soft Tissue Matrix available to more surgeons during our national launch, which is anticipated in the second quarter of 2024.” Avive+ Soft Tissue Matrix™ is a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of healing for nerves.

“我们对外科医生的初步反馈感到满意，并期待着在2024年第二季度的全国发布期间向更多外科医生提供Avive+软组织基质。”Avive+Soft Tissue Matrix™是一种可再吸收的多层胎盘同种异体移植物，在神经愈合的关键阶段提供临时保护和组织分离。

Avive+ is processed and distributed as a 361 tissue product in accordance with U.S. Food and Drug Administration (FDA) Good Tissue Practices under 21 CFR part 1271 regulations. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, complex traumatic injuries, and surgical exposures.

Avive+按照美国食品和药物管理局（FDA）21 CFR第1271部分规定的良好组织规范，作为361组织产品进行加工和分发。神经保护类别涵盖了广泛的损伤和缺陷，包括神经压迫，挤压，复杂的创伤性损伤和手术暴露。

The diversity of these injury types and their anatomical locations present unique challenges for both the surgeon and the patient. To optimize recovery, Axogen provides solutions to adequately address the nerve and the surrounding environment throughout the healing process. “Avive+ Soft Tissue Matrix has great promise for patients who may be suffering from nerve trauma,' stated Brendan MacKay, MD, Associate Professor and Director of Hand and Microvascular Surgery at Texas Tech University Health Sciences Center in Lubbock, TX.

这些损伤类型及其解剖位置的多样性对外科医生和患者都提出了独特的挑战。为了优化恢复，Axogen提供了在整个愈合过程中充分解决神经和周围环境问题的解决方案。德克萨斯州卢伯克德克萨斯理工大学健康科学中心手部和微血管外科副教授、医学博士布伦丹·麦凯（BrendanMackay）表示：“Avive+软组织基质对可能患有神经创伤的患者有很大的希望。”。